問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2026-08-01

鄭樁昱
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

1Cases

2025-03-01 - 2027-08-31

Phase II

Active
A single-therapy, multicenter, repeated-dose phase 2 trial was conducted to evaluate the safety of OBI-858 in subjects with moderate to severe frown lines.
  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites